X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.globenewswire.com/news-release/2024/03/27/2853130/13009/en/Catalyst-Pharmaceuticals-to-Participate-in-the-2024-Cantor-Virtual-Muscular-Dystrophy-Symposium.html
https://www.globenewswire.com//news-release/2023/11/02/2772557/13009/en/Catalyst-Pharmaceuticals-Receives-Two-New-U-S-Patent-Allowances-For-FIRDAPSE.html
https://www.globenewswire.com/news-release/2022/07/12/2477834/13009/en/Catalyst-Pharmaceuticals-Announces-Settlement-of-U-S-Patent-Litigation-and-Resolution-of-Litigation-Challenging-Ruzurgi-Approval-with-Jacobus-Pharmaceutical.html
https://www.ema.europa.eu/en/documents/overview/amifampridine-serb-epar-medicine-overview_en.pdf
https://www.globenewswire.com/news-release/2022/02/03/2378495/13009/en/Catalyst-Pharmaceuticals-Reports-that-the-FDA-Marketing-Approval-Previously-Granted-for-Ruzurgi-is-No-Longer-Valid.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209321
https://www.globenewswire.com/news-release/2022/01/28/2375214/13009/en/Catalyst-Pharmaceuticals-Announces-Issuance-of-Mandate-by-the-U-S-Court-of-Appeals-for-the-11th-Circuit-Directing-the-District-Court-Judge-in-Catalyst-s-Lawsuit-Against-the-FDA-to-.html
https://www.globenewswire.com/news-release/2021/12/06/2346411/0/en/Catalyst-Pharmaceuticals-Announces-DyDo-Pharma-Initiation-of-a-Phase-3-Study-for-FIRDAPSE-amifampridine-in-Japan.html
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-6-2021-1633509984.pdf
https://www.biospace.com/article/appeals-court-supports-catalyst-s-attempt-to-overturn-fda-decision/?s=71
https://www.pharmacompass.com/pdf/news/jacobus-pharmaceuticals-issues-voluntary-worldwide-recall-of-ruzurgi-10-mg-1631596573.pdf
https://www.pharmacompass.com/pdf/news/health-canada-issues-recall-of-meduniks-ruzurgi-amifampridine-1632832791.pdf
https://www.globenewswire.com/news-release/2021/06/28/2253857/13009/en/Catalyst-Pharmaceuticals-Announces-Exclusive-License-and-Supply-Agreement-with-DyDo-Pharma-for-the-Development-and-Commercialization-of-Firdapse-in-Japan.html
https://www.globenewswire.com/news-release/2021/06/28/2254299/13009/en/Catalyst-Pharmaceuticals-Comments-on-Recent-Decision-by-Health-Canada-to-Re-issue-an-NOC-for-Ruzurgi.html
https://www.newswire.ca/news-releases/ruzurgi-r-now-available-to-canadian-lambert-eaton-myasthenic-syndrome-lems-patients-892670272.html
https://www.newswire.ca/news-releases/medunik-canada-expands-its-orphan-disease-portfolio-by-receiving-market-authorization-for-ruzurgi-r--834017561.html
https://www.fdanews.com/articles/198354-judge-recommends-throwing-out-catalysts-suit-against-fda?v=preview
https://endpts.com/an-incensed-catalyst-pharma-sues-the-fda-accusing-agency-of-bowing-to-political-pressure-and-breaking-federal-law/
https://endpts.com/with-a-substantial-discount-to-catalysts-firdapse-is-jacobus-poised-to-win-physician-payer-support-for-off-label-adult-use/
https://www.biopharmadive.com/news/catalyst-dives-as-fda-approves-rivals-rare-disease-drug/554267/
http://www.pharmatimes.com/news/fda_approves_ruzurgifor_children_with_lambert-eaton_myasthenic_syndrome_1286984
https://www.fiercepharma.com/pharma/first-a-pricing-scandal-for-catalyst-s-firdapse-next-off-label-competition
https://www.raps.org/news-and-articles/news-articles/2019/2/sanders-questions-375000-price-tag-for-previousl?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%204%20February
https://www.statnews.com/pharmalot/2018/12/13/catalyst-drug-prices-fentanyl/
https://www.reuters.com/article/catalyst-pharms-fda/u-s-fda-approves-catalyst-pharmas-rare-disease-drug-idUSL4N1Y368E?rpc=401&
https://globenewswire.com/news-release/2018/05/29/1513132/0/en/Catalyst-Pharmaceuticals-Announces-FDA-Acceptance-of-NDA-and-Priority-Review-Status-for-Firdapse-Amifampridine-Phosphate-for-Lambert-Eaton-Myasthenic-Syndrome.html
https://globenewswire.com/news-release/2018/02/12/1339023/0/en/Catalyst-Pharmaceuticals-Announces-Plans-to-Resubmit-New-Drug-Application-for-Firdapse.html
https://endpts.com/catalyst-heads-back-to-the-fda-in-search-of-an-elusive-ok-after-firdapse-scores-high-in-new-phiii/
https://globenewswire.com/news-release/2017/11/27/1206192/0/en/Catalyst-Pharmaceuticals-Announces-Positive-Top-Line-Results-from-Second-Phase-3-Clinical-Trial-of-Firdapse-in-Patients-with-Lambert-Eaton-Myasthenic-Syndrome.html
https://globenewswire.com/news-release/2017/11/21/1198039/0/en/Catalyst-Pharmaceuticals-Announces-Phase-2-Study-of-Firdapse-in-Ambulatory-Patients-with-Spinal-Muscular-Atrophy-SMA.html
https://globenewswire.com/news-release/2017/11/21/1198039/0/en/Catalyst-Pharmaceuticals-Announces-Phase-2-Study-of-Firdapse-in-Ambulatory-Patients-with-Spinal-Muscular-Atrophy-SMA.html
https://globenewswire.com/news-release/2017/10/31/1169571/0/en/Catalyst-Pharmaceuticals-Completes-Enrollment-in-Second-Phase-3-Trial-of-Firdapse-in-Patients-with-Lambert-Eaton-Myasthenic-Syndrome.html
https://globenewswire.com/news-release/2017/03/15/937934/0/en/Catalyst-Pharmaceuticals-Announces-Positive-Data-from-Investigator-Sponsored-Trial-of-Firdapse-in-treating-MuSK-Antibody-Positive-Myasthenia-Gravis.html
http://investors.bmrn.com/releasedetail.cfm?ReleaseID=908731
Market Place
Share 
